News
 July 14, 2008
 RxElite Enters Into a Development, Supply and Marketing Agreement for the Manufacture of an Ophthalmic Solution
July 7, 2008
RxElite, Inc. Announces Implementation of Preferred Contract Awarded With Heritage Valley Health System for Their Anesthetic Gas Products
June 12, 2008
Jonathan Houssian Interview with WallStTv
June 5, 2008
RxElite Inc. Announces $5,000,000 Financing Agreement with NPIL Pharma Inc.
May 27, 2008
RxElite, Inc. announces orders from Physician Sales and Services (PSS) from contract entered into in March
May 20, 2008
RxElite Releases First Quarter Earnings Call
April 21, 2008
RxElite Announces 7 Year Agency Agreement With ACIC Europe Limited to Market Its FineTech Pharmaceuticals
Product Line in Europe and Latin America
April 11, 2008
RxElite Announces Preferred Contract Status Awarded by National Surgical Hospitals for Their Anesthetic Gas Products
April 10, 2008
RxElite Announces Preferred Contract Status Awarded for Their Anesthetic Gas Products by Nueterra Healthcare
April 9, 2008
RxElite, Inc. Refiles Registration Statement:
Ability to Sell Under Prospectus Reinstated
March 31, 2008
RxElite, Inc. announces the dual-source contract award by Surgical Care Affiliates of Sevoflurane and Isoflurane
March 20, 2008
RxElite Awarded Anesthetic Gases Multi-Source Contract by Premier Inc., a Purchasing Network for more than 1,500 U.S. Hospitals and 49,000 Other Healthcare Sites
March 18, 2008
RxElite Notice of Annual Financials Earnings Call
March 10, 2008
RxElite Filling Critical Requirement for Strategic Partners in Asia, Europe, and Australia
January 22, 2008
RxElite Appoints Rick Schindewolf Vice President for Business Development
January 16, 2008
RxElite Appoints Shannon Stith as VP Finance
January 11, 2008
RxElite Announces Acquisition of Assets of FineTech Laboratories
January 7, 2008
/CORRECTION//- RxElite Temporarily Suspends
Sales Under Its Registration Statement
January 4, 2008
RxElite Registration Statement Suspended
January 3, 2008
RxElite Registration Statement Declared Effective by Securities and Exchange Commission
January 3, 2008
RxElite Completes Senior Secured Note Financing
November 26, 2007
RxElite Announces Groundbreaking of New Corporate Facility
November 20, 2007
RxElite Announces 3d Quarter Financials Conference Call
November 8, 2007
RxElite Board of Directors Approves Name and Trading Symbol Change
October 25, 2007
RxElite to Present at Rodman & Renshaw Healthcare Conference
October 24, 2007
CORRECTION - RxElite Files Registration Statement with Securities and Exchange Commission
October 18, 2007
RxElite Appoints New Chairman and CEO; Management Positions for Continued Growth
October 12, 2007
RxElite Files Registration Statement with Securities and Exchange Commission
October 12, 2007
Oppenheimer report - Company Update
August 31, 2007
Money Week reference to RxElite
August 21, 2007
RxElite named one of Entrepreneur Magazine's hot 500 fastest growing business
July,23 2007
Southridge Technology Group, Inc. Common Shares to Commence Trading as SOUT.OB & Announces Closing of $19.6 Million Financing
Meridian, ID --(BUSINESS WIRE)--July 20, 2007 -- Southridge Technology Group, Inc. (OTCBB:SOUT.OB) and RxElite Holdings, Inc., its wholly owned operating subsidiary and developer, manufacturer, and marketer of specialty generic prescription drug products, announced today that its shares will commence trading Monday, July 23, 2007 under the symbol SOUT.OB on the over-the-counter bulletin board. The Company also announced that it closed on approximately $19.6 million of equity financing through the sale of common stock and warrants. The proceeds of this financing will be used for, among other things, costs related to the launch of the company's newly approved generic Sevoflurane, product pipeline development, and general working capital.
"The additional capital from this offering positions the combined company to continue the success of RxElite in its current markets, the expansion and acceleration of its product development activities, and its offering of highly competitive products," commented Daniel Chen, Chairman and CEO of RxElite Holdings, Inc. "Becoming a public company allows RxElite to enjoy broader exposure to the investment community and provide us with access to the capital markets as we continue to expand market share and grow our revenues and earnings."
RxElite has exclusive rights from Minrad International (AMEX:BUF) to market generic Sevoflurane in the United States, which RxElite expects to be its principle product for 2007. Minrad's version of generic Sevoflurane received FDA approval on May 2, 2007. Mr. Chen added, "We anticipate significant gross margin benefits from the launch of generic Sevoflurane in the last 6 months of 2007." The U.S. market for Sevoflurane is estimated at $400 million annually.
Product pipeline development
At present, RxElite has a portfolio of pipeline and marketed specialty products classified into three identifiable business segments: (1) anesthetic gases; (2) sterile liquid dose products; and (3) transdermal patch products.
A series of Abbreviated New Drug Applications (ANDAs) are in various stages of development, and in addition to our internal pipeline, we also have corporate partnerships with Alkem Laboratories Ltd. and Stason Pharmaceuticals, each of which is a significant Asian generic pharmaceutical company, as well as with Zach Systems S.p.A, a European pharmaceutical company. The agreements are for the development, testing and manufacture of a portfolio of products that RxElite has exclusive rights to sell in the U.S. market.
RxElite's customers include hospitals and hospital Group Purchasing Organizations (GPO), national and regional wholesalers, direct retail pharmacy stocking chains, leading homecare companies, and outpatient and ambulatory care clinics
About RxElite Holdings, Inc
.
RxElite Holdings, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.
The full details of the transactions described in this press release can be found in our filings with the Securites and Exchange Commission.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause the our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
June 28, 2007
Oppenheimer report - Company Update
June,15 2007
RxElite and Zach System S.p.A. sign joint venture product development agreement
RxElite Holdings, Inc (Meridian, ID) and Zach System S.p.A. (Milan, Italy), a fine chemical manufacturer and a member company of Zambon Group S.p.A, have announced a joint venture product development agreement. The collaboration will focus on developing generic sterile ophthalmic products for regulated markets and will leverage RxElite's experience in generic drug manufacturing and distribution and Zach System's expertise in developing and manufacturing active pharmaceutical ingredients. Under the terms of the agreement RxElite will be responsible for development, manufacturing and marketing of the drug products in the US while Zach System will be responsible for providing the requisite active pharmaceutical ingredients. Zach System will retain marketing rights for all other regulated markets.
May 31, 2007
Oppenheimer report - Company Update
May 16, 2007
Oppenheimer report - Quarterly Update
May 2, 2007
RxElite announces launch of generic Sevoflurane
On May 2, 2007 RxElite announced that MINRAD International, Inc. received approval from the U.S. Food and Drug Administration to market SojournŠ (Sevoflurane) inhalation anesthetic in the United States. RxElite is Minrad's exclusive marketing and distribution partner for SojournŠ (Sevoflurane) for the United States market.
January 31, 2007
RxElite announces appointment of Patrick Poisson to position of Vice President
RxElite Appoints Patrick Poisson to Position of Vice President - RxElite Holdings, Inc announces the appointment of Patrick Poisson to the position of Vice President, Sterile Products where he will oversee the manufacture and development of products in RxElite's sterile product portfolio. Mr. Poisson joins RxElite from Cardinal Health's Woodstock (IL) sterile products operation where he led the sites clinical manufacturing, project management, and business development groups. During his tenure at Cardinal Health, Mr. Poisson played a key role in commercialization of numerous generic and branded pharmaceutical products.
Prior to joining Cardinal Health, Mr. Poisson was employed with Genentech Inc., in sterile manufacturing. In addition to his more than 15 years of professional experience, Mr. Poisson has been a frequent technical speaker at industry conferences, is the co-author of four peer reviewed aseptic processing research articles, and is a named inventor in three international patents/patent applications. This appointment is designed to enhance the development and deployment of the Sterile Products Pipeline for RxElite. Mr. Poisson holds a B.Sc. from Michigan State University.
|
